HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increase in plasma thrombin-activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation.

Abstract
The causes of thrombosis in antiphospholipid syndrome (APS) remain unknown, though several hypotheses in regard to hypofibrinolysis have been proposed. To clarify the mechanism, we measured plasma levels of thrombin-activatable fibrinolysis inhibitor (TAFI) in APS patients. Both the TAFI antigen (TAFI:Ag) level measured with an ELISA, and thrombin-thrombomodulin-dependent TAFI activity (TAFI:Ac) were elevated in 68 APS patients as compared with those in 66 healthy controls, though they were lower than those in 46 patients with autoimmune diseases. As for the influence of antiphospholipid antibodies (aPL) on TAFI levels, the mean TAFI:Ac level in 39 SLE patients positive for APS was significantly lower than that in 27 SLE patients without APS, whereas there was no difference in TAFI:Ag between those groups. Furthermore, purified IgG from patients positive for aPL, and monoclonal aPL (EY2C9 and 23-1D) inhibited the activation of TAFI in a concentration dependent manner. These results suggest that aPL inhibits TAFI activation by affecting the function of thrombomodulin-thrombin complex through phospholipids. Although TAFI in plasma is elevated in autoimmune diseases including APS, we concluded that an elevated level is not likely a risk factor for thrombosis in APS patients, because of the inhibition of TAFI activation by aPL.
AuthorsMasahiro Ieko, Mika Yoshida, Sumiyoshi Naito, Toru Nakabayashi, Kaoru Kanazawa, Kazuhiro Mizukami, Masaya Mukai, Tatsuya Atsumi, Takao Koike
JournalInternational journal of hematology (Int J Hematol) Vol. 91 Issue 5 Pg. 776-83 (Jun 2010) ISSN: 1865-3774 [Electronic] Japan
PMID20490730 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Antiphospholipid
  • Carboxypeptidase B2
Topics
  • Adult
  • Aged
  • Antibodies, Antiphospholipid (immunology)
  • Antiphospholipid Syndrome (blood, complications)
  • Carboxypeptidase B2 (blood, immunology)
  • Female
  • Humans
  • Lupus Erythematosus, Systemic (blood)
  • Male
  • Middle Aged
  • Risk Factors
  • Thrombosis (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: